New hope for GVHD patients who fail standard therapy?
NCT ID NCT07197112
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a new drug called gecacitinib for people with acute graft-versus-host disease (GVHD) after a stem cell transplant. It is for those who did not get better or could not tolerate the usual second-line treatment. The trial will include 15 adults and aims to see if the drug is safe and helps control the disease.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- gecacitinib hydrochloride tablets
- What this could lead to
- If successful, this could offer a new treatment option for acute GVHD patients who have not responded to standard second-line therapy.
- What could go wrong
- This is a small, early-phase trial with only 15 participants and no control group. The drug may not work or could have side effects. Results may not apply to all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE GRAFT VERSUS HOST DISEASE GRADE II-IV are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.